JAN 21-24

Santa Clara Convention Center

$1999

By JAN. 24 Join Now!

400

Speakers 5-TRACKS
GOV | ACADEMIA GROUP | NONPROFIT -RATES

Speaker Profile

M.D., Section Head/PDT Lead SCCHN, GCD Oncology, Merck
Biography

Jon Cheng, M.D., is Executive Director, Oncology Clinical Research at Merck Research Laboratories (MRL) and is Section Head of Late Stage Malignancies. In this role, he oversees the clinical development of pembrolizumab in multiple solid organ tumors including head/neck and gastrointestinal malignancies, and provides strategic development of biomarkers for immunotherapy. Dr. Cheng joined Merck in 2008 after 11 years at Fox Chase Cancer Center, where he continues to see patients as an Adjunct Professor. He had previous responsibilities at Merck developing novel combinations within the Merck pipeline, incorporating biomarkers and companion diagnostic development into clinical trials, and led a number of registrational activities.

Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from both industry and medical representatives about their novel and innovative programs, which have the goal of expediting immunotherapy cancer treatments and delivering better patient outcomes.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).